SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
AbbVie's office in South San Francisco, California
Parkinson’s disease
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.
September 27, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of the U.S. Securities and Exchange Commission in Washington, DC
Alzheimer’s disease
Cassava Agrees to Pay $40M Fine to Resolve SEC Probe as Company Hit With New Lawsuit
Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District Court of Texas, claiming that the company misled investors regarding the Phase IIb performance of its Alzheimer’s disease drug candidate.
September 27, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Roche Diagnostics building in California
Immunology and inflammation
Roche Looks to Push Gazyva Into Lupus Nephritis With Promising Late-Stage Data
In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis versus placebo, positioning Roche’s therapeutic antibody for expansion into the indication.
September 27, 2024
 · 
2 min read
 · 
Tristan Manalac
Human hand and ai Roboter hand symbolizing teamwork working on a pie chart. Arms point fingers hold pieces diagram chart. Earn money together with artificial intelligence.
Venture capital
ARCH Fuels Up With $3B to Support Next Class of AI Biotechs
ARCH Venture Partners is the latest venture capital firm to raise a multi-billion-dollar fund. The cash will be used to support new startups working with AI.
September 26, 2024
 · 
1 min read
 · 
Annalee Armstrong
Job resume document out from laptop. Hands holding cv resume papers. Human resources management concept, searching professional staff, work. Found right resume. Vector illustration in flat style
Career Advice
Telling the Right Story: Overselling, Underselling Can Hurt Your Candidacy
During the job application and interview process, candidates who lie to prospective employers and those who don’t properly highlight their accomplishments can find it difficult to land—or keep—their next role. We asked experts how to sell yourself positively and honestly.
September 26, 2024
 · 
5 min read
 · 
Angela Gabriel
Drug Development
AI Return on Investment: Just Because We Can, Should We?
In this episode, Lori and guests continue their exploratory discussion on AI and focus on the challenges of globalization and return on investment.
September 26, 2024
 · 
1 min read
 · 
Lori Ellis
Corporate headquarters of Novo Nordisk in Denmark
Collaboration
Novo, Evotec Ink Stem Cell Partnership as Drugmaker Looks to Expand Pipeline
While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites in Germany and Italy to support the development of next-generation cell therapies.
September 26, 2024
 · 
2 min read
 · 
Tristan Manalac
Sign in front of Pfizer in Quebec, Canada
Sickle cell disease
Pfizer Takes Sickle Cell Drug Oxbryta Off Global Market, Cites Risk of Death
Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in patients with sickle cell disease. Guggenheim Securities analysts said the setback increases investor frustrations with the company’s business development track record.
September 26, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of Novo Nordisk's office in Fremont, California
Drug Development
Novo’s Ozempic Potentially Linked to Lower Opioid Overdose Risk in Diabetics
A retrospective cohort study of more than 33,000 patients with type 2 diabetes showed that Novo Nordisk’s GLP-1 may lower the risk of opioid overdose by 42% to up to 68%.
September 26, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS